Navigation Links
MannKind Corporation Reports Second Quarter Financial Results
Date:8/11/2008

of 2008 as compared to the same period in 2007. The increase in G&A expenses for the first six months was primarily due to increases in salary related expenses and stock-based compensation expense, partially offset by lower professional service fees.

We expect G&A expenses to increase during the remainder of 2008 as a result of increased salary and stock-based compensation related expenses and professional service fees.

The net loss for the second quarter of 2008 was $79.8 million, or $0.79 per share, based on 101.4 million weighted average shares outstanding. This compares to a net loss of $72.0 million, or $0.98 per share, based on 73.4 million weighted average shares outstanding for the second quarter of 2007.

The net loss for the first half of 2008 was $151.2 million, or $1.49 per share based on 101.4 million shares outstanding, compared with a net loss of $145.1 million, or $1.98 per share based on 73.4 million shares outstanding, for the first half of 2007.

Cash and cash equivalents were $180.5 million at June 30, 2008, $269.1 million at March 31, 2008 and $368.3 million at December 31, 2007.

"This is an exciting time for MannKind Corporation," commented Alfred Mann, Chairman and CEO. "We are only about three weeks from completion of our final two pivotal trials for Technosphere Insulin. Importantly, our team was satisfied with the outcome from our July 14 pre-NDA meeting with the FDA. Our science, preclinical and clinical programs have enabled us to target year-end to complete preparation of the NDA, though that is an aggressive target."

Hakan Edstrom, President and COO, added, "Our new Danbury factory is virtually complete and we are looking forward to the dedication on September 17. This factory is being equipped in modular steps to meet our expected demand for Technosphere Insulin. Our other products are also moving forward, and clinical progress for our GLP-1 formulation and two cancer vaccines continues to be ve
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports First Quarter Financial Results
4. MannKind to Present at the Morgan Stanley Healthcare Conference
5. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. MannKind Corporation Response to Recent Market Events
8. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
9. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. MannKind to Present at the Wachovia 2008 Healthcare Conference
11. MannKind to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained from ... is dominated by four major players contributing to ... players include GE Healthcare (U.K.), Siemens AG (Germany), ... Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , ... attributed to its strong product portfolio, which includes ...
(Date:12/17/2014)... December 17, 2014 Once more, EMAAR ... a larger packaged waste water treatment plant to phase ... Economic City (KAEC). Two years ago Bioshaft successfully supplied ... Development, serving two residential towers with an occupancy of ... a quarter million gallons per day and was signed ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Chest Physicians (ACCP) Guidelines Will Increase ... Use of Trellis(R) Peripheral Infusion System, NORTHBROOK, ... (ACCP) has published new evidence-based clinical guidelines for,physicians that ... for acute iliofemoral deep vein thrombosis (DVT) in,conjunction with ...
... are everywhere from the air we breathe and the food ... are innocuous or even beneficial, and only a handful pose any ... unwanted intruder? , Research from the University of Wisconsin-Madison suggests ... , A study appearing online this week in the Proceedings ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today ... the,Company,s novel investigational non-nucleoside reverse transcriptase,inhibitor (NNRTI) for ... Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC ... of HIV Research, Chelsea and Westminster,Hospital, will present ...
Cached Biology Technology:Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT 2Symbiotic microbes induce profound genetic changes in their hosts 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 3
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Conn., May 22, 2012 /PRNewswire-iReach/ -- Global ... bird discounted registration for three significant international healthcare conferences: ... – Latin America October 29-30, ... Annual World Health Care Congress – Latin America ...
... Antibodies that help to stop the HIV virus have ... Center isolated the antibodies from immune cells called B cells ... showed that the B cells in breast milk can generate ... HIV-1 can be transmitted from mother to child via ...
... Researchers at the Hebrew University of Jerusalem have ... cells from stem cells of Fragile X patients. The ... restoration of normal gene expression in Fragile X patients. ... of inherited mental retardation, affecting hundreds of thousands of ...
Cached Biology News:Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information 2Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information 3Newly discovered breast milk antibodies help neutralize HIV 2Newly discovered breast milk antibodies help neutralize HIV 3Stem cell research paves way for progress on dealing with Fragile X retardation 2
... Software reads and processes raw ... microarray data for analysis. ... one 1-year license for Feature ... ,one CD-ROM containing Feature Extraction ...
... CHEMICONs ELF 97 Cytological Labeling Kit provides ... the detection of cellular targets, including cell-surface ... Cytological Labeling Kit contains the patented ELF ... fluorescent yellow-green precipitate at the site of ...
... Many differences exist between the various commercial ... glass slide used, the length and GC ... and the manufacturing protocol employed all influence ... analysis. With all the different variables ...
... SYBR Safe DNA Gel Stain combo offers these benefits: ... these same products separately ... Eliminates risks to yourself, ... RNA fragments from 100 bp to >30 kb. UltraPure ...
Biology Products: